Michail_Petrov-96/iStock via Getty Images Lexicon Pharmaceuticals ( NASDAQ: LXRX ) said that efficacy and safety data for its drug sotagliflozin in the treatment of patients with type 1 diabetes and chronic kidney disease will be presented this weekend at the Annual Conference of the Association of Diabetes Care & Education Specialists, which will be held Aug. 9-12 in New Orleans. The data will be presented via a poster presentation on Aug.
10, along with a poster presentation of sotagliflozin as an add-on therapy for basal insulin–treated type 2 diabetes and another on patient-reported burden of disease in diabetic peripheral neuropathic pain, according to a statement. Lexicon already markets sotagliflozin under the name Inpefa. The product is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors, according to the drug’s website.
More on Lexicon Pharmaceuticals Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success Lexicon Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call Presentation Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2024 Earnings Call Transcript Lexicon Pharmaceuticals Q2 2024 Earnings Preview Lexicon gains as diabetes therapy undergoes FDA review.
